| Embracing genetic diversity to improve black health A Oni-Orisan, Y Mavura, Y Banda, TA Thornton, R Sebro New England Journal of Medicine 384 (12), 1163-1167, 2021 | 103 | 2021 |
| Epoxyeicosatrienoic acids and cardioprotection: the road to translation A Oni-Orisan, N Alsaleh, CR Lee, JM Seubert Journal of molecular and cellular cardiology 74, 199-208, 2014 | 93 | 2014 |
| Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study A Oni-Orisan, ML Edin, JA Lee, MA Wells, ES Christensen, KC Vendrov, ... Journal of lipid research 57 (1), 109-119, 2016 | 74 | 2016 |
| Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism KN Theken, Y Deng, RN Schuck, A Oni-Orisan, TM Miller, ... American Journal of Physiology-Endocrinology and Metabolism 302 (5), E500-E509, 2012 | 57 | 2012 |
| Gene expression in African Americans, Puerto Ricans and Mexican Americans reveals ancestry-specific patterns of genetic architecture L Kachuri, ACY Mak, D Hu, C Eng, S Huntsman, JR Elhawary, N Gupta, ... Nature genetics 55 (6), 952-963, 2023 | 55 | 2023 |
| Characterization of statin low-density lipoprotein cholesterol dose-response using electronic health records in a large population-based cohort A Oni-Orisan, TJ Hoffmann, D Ranatunga, MW Medina, E Jorgenson, ... Circulation: Genomic and Precision Medicine 11 (9), e002043, 2018 | 44 | 2018 |
| Blood pressure–associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding X Bai, KD Mangum, RA Dee, GA Stouffer, CR Lee, A Oni-Orisan, ... The Journal of clinical investigation 127 (2), 670-680, 2017 | 40 | 2017 |
| Effect of SLCO1B1 T521C on Statin‐Related Myotoxicity With Use of Lovastatin and Atorvastatin B Lu, L Sun, M Seraydarian, TJ Hoffmann, MW Medina, N Risch, ... Clinical Pharmacology & Therapeutics 110 (3), 733-740, 2021 | 27 | 2021 |
| Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice A Oni-Orisan, Y Deng, RN Schuck, KN Theken, ML Edin, FB Lih, K Molnar, ... Prostaglandins & other lipid mediators 104, 67-73, 2013 | 27 | 2013 |
| Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? A Oni-Orisan, DE Lanfear Cardiology in review 22 (5), 193-198, 2014 | 23 | 2014 |
| Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients OM Dong, A Li, O Suzuki, A Oni-Orisan, R Gonzalez, GA Stouffer, CR Lee, ... Pharmacogenomics 19 (9), 771-782, 2018 | 20 | 2018 |
| Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system AE Fohner, DK Ranatunga, KK Thai, BL Lawson, N Risch, A Oni-Orisan, ... Pharmacogenetics and genomics 29 (8), 192-199, 2019 | 18 | 2019 |
| Low-and high-density lipoprotein cholesterol and dementia risk over 17 years of follow-up among members of a large health care plan EL Ferguson, SC Zimmerman, C Jiang, M Choi, K Swinnerton, ... Neurology 101 (21), e2172-e2184, 2023 | 17 | 2023 |
| The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change A Oni-Orisan, T Haldar, DK Ranatunga, MW Medina, C Schaefer, ... NPJ genomic medicine 5 (1), 1, 2020 | 16 | 2020 |
| Metformin cessation and dementia incidence SC Zimmerman, EL Ferguson, V Choudhary, DK Ranatunga, ... JAMA network open 6 (10), e2339723-e2339723, 2023 | 14 | 2023 |
| Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens O Kehinde, LB Ramsey, A Gaedigk, A Oni‐Orisan Clinical Pharmacology & Therapeutics 114 (1), 69-76, 2023 | 13 | 2023 |
| QT interval dynamics and cardiovascular outcomes: a cohort study in an integrated health care delivery system N Mantri, M Lu, JG Zaroff, N Risch, T Hoffmann, A Oni‐Orisan, C Lee, ... Journal of the American Heart Association 10 (19), e018513, 2021 | 13 | 2021 |
| Polygenic risk score and statin relative risk reduction for primary prevention of myocardial infarction in a real‐world population A Oni‐Orisan, T Haldar, MAS Cayabyab, DK Ranatunga, TJ Hoffmann, ... Clinical Pharmacology & Therapeutics 112 (5), 1070-1078, 2022 | 10 | 2022 |
| Association between the EPHX2 p. Lys55Arg polymorphism and prognosis following an acute coronary syndrome A Oni-Orisan, S Cresci, PG Jones, KN Theken, JA Spertus, CR Lee Prostaglandins & other lipid mediators 138, 15-22, 2018 | 10 | 2018 |
| Acute decompensated heart failure: evolving literature and implications for future practice JD Cicci, BN Reed, EB McNeely, A Oni‐Orisan, JH Patterson, JE Rodgers Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34 (4 …, 2014 | 8 | 2014 |
